awmsg logo



infliximab (Inflectra®)


Reference No. 2253

Publication date:
11/03/2015


Appraisal information

infliximab (Inflectra®) 100 mg powder for concentrate for solution for infusion


Company: Hospira UK Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 19/11/2014
AWMSG meeting date: 17/12/2014
   
   
Submission Type: Full Submission
Status: Partially superseded
Advice No: 4214
Ministerial ratification: 10/03/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE PARTIALLY SUPERSEDED BY NICE GUIDANCE (TA329, TA375, TA383) NICE GUIDANCE ISSUED FEBRUARY 2015, JANUARY 2016, FEBRUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Infliximab (Inflectra®) is recommended as an option for restricted use within NHS Wales. Infliximab (Inflectra®▼ should be prescribed within its licensed indications in accordance with NICE or AWMSG guidance for infliximab (Remicade®), the reference product. Infliximab (Inflectra®▼)should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download